Evidence map›Paper›PMID 24854628›Full record

Trial reportAtherosclerosis2014

ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment.

Hironobu Akao, Eliana Polisecki, Ernst J Schaefer, Stella Trompet, Michele Robertson, Ian Ford, J Wouter Jukema, Anton J M de Craen, Christopher Packard, Brendan M Buckley and 2 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Atherosclerosis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Observational
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 5 countries.

Hironobu AkaoLipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University and Tufts University School of Medicine, Boston, MA, USA; Department of Cardiology, Kanazawa Medical University, Uchinada, Japan.
Eliana PoliseckiLipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University and Tufts University School of Medicine, Boston, MA, USA; Boston Heart Diagnostics, Framingham, MA, USA.
Ernst J SchaeferLipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University and Tufts University School of Medicine, Boston, MA, USA; Boston Heart Diagnostics, Framingham, MA, USA.
Stella TrompetDepartment of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands; Department of Gerontology, and Geriatrics, Leiden University Medical Centre, Leiden, The Netherlands.
Michele RobertsonRobertson Centre of Biostatistics, University of Glasgow, Glasgow, Scotland, UK.
Ian FordRobertson Centre of Biostatistics, University of Glasgow, Glasgow, Scotland, UK.
J Wouter JukemaDepartment of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands; Department of Gerontology, and Geriatrics, Leiden University Medical Centre, Leiden, The Netherlands.
Anton J M de CraenDepartment of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands; Department of Gerontology, and Geriatrics, Leiden University Medical Centre, Leiden, The Netherlands.
Christopher PackardDepartment of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland, UK.
Brendan M BuckleyDepartment of Pharmacology and Therapeutics, University College Cork, Cork, Ireland.
Kouji KajinamiDepartment of Cardiology, Kanazawa Medical University, Uchinada, Japan. Electronic address: kajinami@kanazawa-med.ac.jp.
PROspective Study of Pravastatin in the Elderly at Risk Investigator
Leiden University · NLUniversity of Glasgow · GBKanazawa Medical University · JPTufts University · USUniversity College Cork · IE

Funding

Pharmacogenetics of the Statin ResponseR01HL074753 · NHLBI · TUFTS UNIVERSITY BOSTON · PI SCHAEFER, ERNST JOHN · 2003 to 2006
$3.1M
NHLBI NIH HHS R01 HL074753NHLBI NIH HHS R01 HL74753
6 · The paper itself

Abstract

aimsOur goals were to examine the relationships of a specific ATP-binding cassette transporter A1 (ABCA1) variant, rs2230806 (R219K), on baseline lipids, low-density lipoprotein cholesterol (LDL-C) lowering due to pravastatin, baseline heart disease, and cardiac endpoints on trial. METHODS AND

resultsThe ABCA1 R219K variant was assessed in 5414 participants in PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) (mean age 75.3 years), who had been randomized to pravastatin 40 mg/day or placebo and followed for a mean of 3.2 years. Of these subjects 47.6% carried the variant, with 40.0% carrying one allele, and 7.6% carrying both alleles. No effects on baseline LDL-C levels were noted, but mean HDL-C increased modestly according to the number of variant alleles being present (1.27 vs 1.28 vs 1.30 mmol/L, p = 0.024). No relationships between the presence or absence of this variant and statin induced LDL-C lowering response or CHD at baseline were noted. However within trial those with the variant as compared to those without the variant, the overall adjusted hazard ratio for new cardiovascular disease (fatal CHD, non-fatal myocardial infarction, or fatal or non-fatal stroke) was 1.22 (95% CI 1.06-1.40, p = 0.006), while for those in the pravastatin group it was 1.41 (1.15-1.73, p = 0.001), and for those in the placebo group it was 1.08 (0.89-1.30, p = 0.447) (p for interaction 0.058).

conclusionOur data indicate that subjects with the ABCA1 R219K variant may get significantly less heart disease risk reduction from pravastatin treatment than those without the variant.

Indexed as

Polymorphism, Single NucleotideAgedAllelesATP Binding Cassette Transporter 1Cholesterol, HDLCholesterol, LDLCoronary DiseaseFemaleGenotypeHeart DiseasesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMyocardial InfarctionPravastatinProportional Hazards ModelsABCA1 protein, humanATP Binding Cassette Transporter 1Cholesterol, HDLCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsPravastatinABCA1 geneHeart disease risk reductionLow-density lipoprotein cholesterol lowering responseStatins

Identifiers

PMID24854628
PMCPMC4556353
OpenAlexW2136855418

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.